Daiichi Sankyo Company, Limited - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DSNKY Over the counter 2834 www.daiichisankyo.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Daiichi Sankyo Company, Limited

Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight - Mar 9th, 2026 3:31 pm
Anticoagulants Market Competitive Analysis Report 2025: Key Players Analysis, Profiles, Product Developments, Mergers, Strategic Collaborations, and Revenue Forecast Insights to 2033 - Mar 9th, 2026 4:29 am
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer - Mar 9th, 2026 12:30 am
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - Mar 6th, 2026 3:13 am
Daiichi and GAIA join forces to commercialise digital cardiovascular therapy - Mar 5th, 2026 5:28 am
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. - Mar 5th, 2026 12:00 am
What Daiichi Sankyo Company (TSE:4568)'s ENHERTU EMA Filing and AI Oncology Push Mean For Shareholders - Feb 27th, 2026 5:10 am
New Strong Sell Stocks for February 25th - Feb 25th, 2026 2:34 am
SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Technology - Feb 23rd, 2026 5:00 am
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi - Feb 20th, 2026 3:23 am
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D - Feb 19th, 2026 5:00 pm
European Stocks Lower in Thursday Trading; ECB Says Economy Resilient but Outlook Remains 'Challenging' - Feb 19th, 2026 10:17 am
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer - Feb 19th, 2026 12:30 am
BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics - Feb 17th, 2026 5:45 am
3 Global Stocks Estimated To Be Undervalued By Up To 49.8% - Feb 10th, 2026 2:38 am
Asian Market Value Picks: Nanjing Leads Biolabs And 2 More Stocks Trading Below Estimated Worth - Feb 5th, 2026 9:38 pm
3 Asian Stocks Estimated To Be Trading At Up To 49.1% Below Intrinsic Value - Feb 5th, 2026 3:34 pm
February 2026's Global Stocks Trading Below Estimated Value - Feb 5th, 2026 2:38 am
FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway - Feb 4th, 2026 8:11 am
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo - Feb 4th, 2026 5:00 am